keyword
Keywords Inflammatory bowel disease, tn...

Inflammatory bowel disease, tnf, adalimumab

https://read.qxmd.com/read/38496097/granulomas-galore-concomitant-granulomatous-infections-in-a-patient-with-crohn-s-disease
#1
Michael Gianarakis, Alexander Gianarakis, Safia Ahmed, John Pueringer, Ushan Ranasinghe
Tumor necrosis factor (TNF)-alpha inhibitors are effective biologics in the treatment of inflammatory bowel disease; however, they increase susceptibility to opportunistic infections. We report a case of a 74-year-old female with Crohn's disease who developed concomitant pulmonary tuberculosis ( Mycobacterium tuberculosis [MTB]) and Histoplasmosis capsulatum  infection while on adalimumab. Co-infection is rare in patients on TNF-alpha inhibitor therapy, and most cases have been reported in patients with human immunodeficiency virus (HIV)...
February 2024: Curēus
https://read.qxmd.com/read/38493113/predictive-biomarkers-for-anti-tnf-alpha-therapy-in-ibd-patients
#2
REVIEW
Manoj Kumar, Selvasankar Murugesan, Nazira Ibrahim, Mamoun Elawad, Souhaila Al Khodor
Inflammatory bowel disease (IBD) is a chronic gastrointestinal condition characterized by severe gut inflammation, commonly presenting as Crohn's disease, ulcerative colitis or categorized as IBD- unclassified. While various treatments have demonstrated efficacy in adult IBD patients, the advent of anti-TNF therapies has significantly revolutionized treatment outcomes and clinical management. These therapies have played a pivotal role in achieving clinical and endoscopic remission, promoting mucosal healing, averting disease progression, and diminishing the necessity for surgery...
March 16, 2024: Journal of Translational Medicine
https://read.qxmd.com/read/38476237/poor-prognostic-factors-of-pharmacokinetic-origin-predict-outcomes-in-inflammatory-bowel-disease-patients-treated-with-anti-tumor-necrosis-factor-%C3%AE
#3
JOURNAL ARTICLE
Elizabeth A Spencer, Marla C Dubinsky, Michael A Kamm, Maria Chaparro, Paolo Gionchetti, Fernando Rizzello, Javier P Gisbert, Emily K Wright, Julien D Schulberg, Amy L Hamilton, Dermot P B McGovern, Thierry Dervieux
INTRODUCTION: We evaluated baseline Clearance of anti-tumor necrosis factors and human leukocyte antigen variant (HLA DQA1*05) in combination as poor prognostic factors (PPF) of pharmacokinetic (PK) origin impacting immune response (formation of antidrug antibodies) and disease control of inflammatory bowel disease (IBD) patients treated with infliximab or adalimumab. METHODS: Baseline Clearance was estimated in IBD patients before starting treatment using weight and serum albumin concentrations...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38463352/is-tumor-necrosis-factor-%C3%AE-monoclonal-therapy-with-proactive-therapeutic-drug-monitoring-optimized-for-inflammatory-bowel-disease-network-meta-analysis
#4
JOURNAL ARTICLE
Fang-Yuan Zheng, Kai-Si Yang, Wen-Cheng Min, Xin-Zhu Li, Yu Xing, Shuai Wang, Ying-Shi Zhang, Qing-Chun Zhao
BACKGROUND: The efficacy and safety of anti-tumor necrosis factor-α (TNF-α) monoclonal antibody therapy [adalimumab (ADA) and infliximab (IFX)] with therapeutic drug monitoring (TDM), which has been proposed for inflammatory bowel disease (IBD) patients, are still controversial. AIM: To determine the efficacy and safety of anti-TNF-α monoclonal antibody therapy with proactive TDM in patients with IBD and to determine which subtype of IBD patients is most suitable for proactive TDM interventions...
February 27, 2024: World Journal of Gastrointestinal Surgery
https://read.qxmd.com/read/38457414/contrast-enhanced-endoscopic-ultrasound-detects-early-therapy-response-following-anti-tnf-therapy-in-patients-with-ulcerative-colitis
#5
JOURNAL ARTICLE
Mark Ellrichmann, Berenice Schulte, Claudio C Conrad, Stephan Schoch, Johannes Bethge, Marcus Seeger, Robert Huber, Madita Goeb, Alexander Arlt, Susanna Nikolaus, Christoph Röcken, Stefan Schreiber
BACKGROUND AND AIM: Though colonoscopy plays a crucial role in assessing active ulcerative colitis (aUC), its scope is limited to the mucosal surface. Endoscopic ultrasound (EUS) coupled with contrast-enhancement (dCEUS) can precisely quantify bowel wall thickness and microvascular circulation, potentially enabling the quantitative evaluation of inflammation.We conducted a prospective, longitudinal study to assess therapy response using dCEUS in aUC patients undergoing treatment with adalimumab (ADA) or infliximab (IFX)...
March 8, 2024: Journal of Crohn's & Colitis
https://read.qxmd.com/read/38456916/adalimumab-as-a-cause-of-kidney-injury-in-patients-with-crohn-s-disease
#6
JOURNAL ARTICLE
Krzysztof Skoczyński, Jan Koziej, Sylwia Szymańska, Łukasz Obrycki, Ryszard Grenda, Mieczysław Litwin
INTRODUCTION: Adalimumab (ADM) is a recombinant human monoclonal antibody (anti-TNFα) used to treat inflammatory bowel diseases. It can cause kidney injury (KI). CASE DIAGNOSIS/TREATMENT: We describe two pediatric patients with Crohn's disease (CD) in whom ADM therapy was associated with kidney injury (KI). The drug was discontinued in both cases. For the first patient, changes were irreversible despite intensive glucocorticosteroid (GCS) therapy. For the second patient, discontinuation of ADM led to an improvement in kidney function...
March 8, 2024: Pediatric Nephrology
https://read.qxmd.com/read/38401525/blood-gene-expression-biomarkers-of-response-to-anti-tnf-drugs-in-pediatric-inflammatory-bowel-diseases-before-initiation-of-treatment
#7
JOURNAL ARTICLE
Sara Salvador-Martín, Gianluca Rubbini, Perceval Vellosillo, Paula Zapata-Cobo, Marta Velasco, Laura M Palomino, Susana Clemente, Oscar Segarra, Ana Moreno-Álvarez, Ana Fernández-Lorenzo, Begoña Pérez-Moneo, Montserrat Montraveta, Cesar Sánchez, Mar Tolín, Inés Loverdos, María José Fobelo, Victor Manuel Navas-López, Lorena Magallares, Ruth García-Romero, Ricardo Torres-Peral, Alejandro Rodríguez, Ferrán Bossacoma, Vicente Merino-Bohórquez, Enrique Salcedo, Rebeca Álvarez, Ana Dopazo, María Sanjurjo-Sáez, Luis A López-Fernández
BACKGROUND/AIMS: Changes in gene expression profiles among individuals with inflammatory bowel diseases (IBDs) could potentially influence the responsiveness to anti-TNF treatment. The aim of this study was to identify genes that could serve as predictors of early response to anti-TNF therapies in pediatric IBD patients prior to the initiation of treatment. METHODS: We conducted a prospective, longitudinal, and multicenter study, enrolling 24 pediatric IBD patients aged less than 18 years who were initiating treatment with either infliximab or adalimumab...
February 23, 2024: Biomedicine & Pharmacotherapy
https://read.qxmd.com/read/38387105/mrna-1273-vaccinated-inflammatory-bowel-disease-patients-receiving-tnf-inhibitors-develop-broad-and-robust-sars-cov-2-specific-cd8-t-cell-responses
#8
JOURNAL ARTICLE
Jet van den Dijssel, Mariël C Duurland, Veronique Al Konijn, Laura Yl Kummer, Ruth R Hagen, Lisan H Kuijper, Luuk Wieske, Koos Pj van Dam, Eileen W Stalman, Maurice Steenhuis, Dionne M Geerdes, Juk Yee Mok, Angela Hm Kragten, Charlotte Menage, Lianne Koets, Barbera Veldhuisen, Niels Jm Verstegen, C Ellen van der Schoot, Wim Je van Esch, Geert Ram D'Haens, Mark Löwenberg, Adriaan G Volkers, Theo Rispens, Taco W Kuijpers, Filip Eftimov, Klaas Pjm van Gisbergen, S Marieke van Ham, Anja Ten Brinke, Carolien E van de Sandt
SARS-CoV-2-specific CD8+ T cells recognize conserved viral peptides and in the absence of cross-reactive antibodies form an important line of protection against emerging viral variants as they ameliorate disease severity. SARS-CoV-2 mRNA vaccines induce robust spike-specific antibody and T cell responses in healthy individuals, but their effectiveness in patients with chronic immune-mediated inflammatory disorders (IMIDs) is less well defined. These patients are often treated with systemic immunosuppressants, which may negatively affect vaccine-induced immunity...
February 21, 2024: Journal of Autoimmunity
https://read.qxmd.com/read/38383265/risk-of-tuberculosis-with-anti-tnf-therapy-in-indian-patients-with-inflammatory-bowel-disease-despite-negative-screening
#9
JOURNAL ARTICLE
Suprabhat Giri, Sukanya Bhrugumalla, Akash Shukla, Sagar Gangadhar, Srujan Reddy, Sumaswi Angadi, Leela Shinde, Aditya Kale
BACKGROUND AND STUDY AIMS: Tuberculosis (TB) is a well-recognized adverse effect associated with using biological therapy to manage various autoimmune conditions. There is a dearth of information about the development of TB after using anti-TNF agents in patients with inflammatory bowel disease (IBD) from TB-endemic countries like India. This study aimed to estimate the risk of TB and its predictors after treatment with anti-TNF agents in patients with IBD. PATIENTS AND METHODS: The present study is a retrospective analysis of data of patients with IBD from two tertiary care centers in India receiving anti-TNF therapy...
February 21, 2024: Arab Journal of Gastroenterology: the Official Publication of the Pan-Arab Association of Gastroenterology
https://read.qxmd.com/read/38377462/disseminated-mycobacterial-infection-with-reactive-polyarthritis-poncet-s-disease-during-immune-suppressive-treatment-including-ustekinumab-for-pediatric-crohn-s-disease
#10
JOURNAL ARTICLE
Chiara Minotti, Paola Costenaro, Daniele Donà, Monica Zuliani, Luca Bosa, Alberta Leon, Giorgio Perilongo, Paola Gaio, Giorgia Martini, Mara Cananzi
BACKGROUND: The incidence of pediatric inflammatory bowel disease is increasing. tumor necrosis factor alpha inhibitors medicines improved the prognosis of affected subjects. Nonetheless, a proportion of patients do not respond or lose response to treatment. Newer biologics, like ustekinumab, have been approved for adults. The pediatric off-label use of these drugs is increasing, despite limited safety evidence. We report a case of disseminated mycobacterial infection (MI) presenting with reactive polyarthritis (Poncet's disease, PD) in a girl with Crohn's disease receiving various immunosuppressants, including ustekinumab...
February 20, 2024: Pediatric Infectious Disease Journal
https://read.qxmd.com/read/38367209/crohn-s-patient-serum-proteomics-reveals-response-signature-for-infliximab-but-not-vedolizumab
#11
JOURNAL ARTICLE
Carlos G Gonzalez, Toer W Stevens, Bram Verstockt, David J Gonzalez, Geert D'Haens, Parambir S Dulai
BACKGROUND: Crohn's disease is a chronic inflammatory bowel disease that affects the gastrointestinal tract. Common biologic families used to treat Crohn's are tumor necrosis factor (TNF)-α blockers (infliximab and adalimumab) and immune cell adhesion blockers (vedolizumab). Given their differing mechanisms of action, the ability to monitor response and predict treatment efficacy via easy-to-obtain blood draws remains an unmet need. METHODS: To investigate these gaps in knowledge, we leveraged 2 prospective cohorts (LOVE-CD, TAILORIX) and profiled their serum using high-dimensional isobaric-labeled proteomics before treatment and 6 weeks after treatment initiation with either vedolizumab or infliximab...
February 17, 2024: Inflammatory Bowel Diseases
https://read.qxmd.com/read/38338289/adalimumab-biosimilar-in-pediatric-inflammatory-bowel-disease-a-retrospective-study-from-the-sicilian-network-for-inflammatory-bowel-disease-sn-ibd
#12
JOURNAL ARTICLE
Valeria Dipasquale, Salvatore Pellegrino, Marco Ventimiglia, Michele Citrano, Francesco Graziano, Maria Cappello, Anita Busacca, Ambrogio Orlando, Salvatore Accomando, Claudio Romano, Sicilian Network For Inflammatory Bowel Disease
BACKGROUND: The utilization of anti-tumor necrosis factor-α (anti-TNF-α) biosimilars in inflammatory bowel disease (IBD) is constantly increasing. However, pediatric data are limited. This study aimed to assess the effectiveness and safety of adalimumab biosimilar (ADL-BioS) in pediatric IBD patients. METHODS: All consecutive pediatric IBD patients from the Sicilian Network for Inflammatory Bowel Disease cohort treated with ADL-BioS from 2019 to 2021 were recruited...
February 4, 2024: Healthcare (Basel, Switzerland)
https://read.qxmd.com/read/38314175/an-update-on-anti-tnf-biosimilar-switching-real-world-clinical-effectiveness-and-safety
#13
JOURNAL ARTICLE
Susanna Meade, Elizabeth Squirell, Thomas Tam Hoang, James Chow, Gregory Rosenfeld
BACKGROUND: Biological medications for inflammatory bowel disease (IBD) account for a significant burden on provincial budgets. In an effort to curb these rising costs, nationwide switching to biosimilars is expected to be complete in Canada before the end of 2023. Biosimilar products do not require the same rigor for licensing as the originator and therefore there has been appropriate scepticism as to how biosimilars will perform in real-world practice. METHODS: We have performed a systematic review including real-world observational studies of adult patients with IBD...
February 2024: Journal of the Canadian Association of Gastroenterology
https://read.qxmd.com/read/38313324/calcific-constrictive-pericarditis-following-tumour-necrosis-factor-alpha-inhibition
#14
Brian Cunneen, Hafiz Hussein, Jenna O'Sullivan, Ibrahim Yearoo
BACKGROUND: Tumour necrosis factor (TNF)-alpha inhibition is a core therapeutic avenue for a broad range of inflammatory and autoimmune disorders including rheumatoid arthritis and inflammatory bowel disease, as well as dermatological conditions such as hidradenitis suppurativa. Adalimumab has become one of the most common TNF-alpha-inhibiting agents, which is used for many of these conditions. Treatment with such agents is associated with numerous systemic side effects, though cardiac complications remain relatively rare...
February 2024: European Heart Journal. Case Reports
https://read.qxmd.com/read/38243962/development-of-morphea-following-treatment-with-an-ada-biosimilar-a-case-report
#15
Aliki I Venetsanopoulou, Konstantina Mavridou, Eleftherios Pelechas, Paraskevi V Voulgari, Alexandros A Drosos
BACKGROUND: Tumor necrosis factor alpha (TNFα) is a pivotal cytokine involved in the pathogenesis of certain inflammatory diseases, such as rheumatoid arthritis (RA), spondyloarthropathies, and inflammatory bowel diseases. In the last two decades, TNFα inhibitors (TNFi) have revolutionized the treatment and outcome of the above disorders. However, the use of TNFi has been associated with the development of many autoimmune phenomena and paradoxical skin manifestations that may present as the same type of clinical indications for which the TNFi effectively used...
January 12, 2024: Current Rheumatology Reviews
https://read.qxmd.com/read/38221908/treatment-persistence-and-switching-patterns-of-abp-501-in-european-patients-with-inflammatory-bowel-disease
#16
JOURNAL ARTICLE
Ran Jin, Silvia Kruppert, Florian Scholz, Isabelle Bardoulat, Khalil Karzazi, Greg Kricorian, James L O'Kelly, Walter Reinisch
BACKGROUND: Approval of the adalimumab (ADA) biosimilar ABP 501 for inflammatory bowel disease (IBD) indications was based on the principle of extrapolation, without indication-specific clinical trial data. OBJECTIVES: To evaluate the real-world treatment patterns of ABP 501 in patients with IBD. DESIGN: Retrospective analysis of pharmacy claims data from Germany and France. METHODS: Continuously insured adult IBD patients who initiated ABP 501 between October 2018 and March 2020 were included...
2024: Therapeutic Advances in Gastroenterology
https://read.qxmd.com/read/38161925/drug-induced-hidradenitis-suppurativa-a-case-report
#17
Abraham Kisule, Vivek Kak, Chidamber Alamelumangapuram, Ciji Robinson
Hidradenitis suppurativa (HS) is a chronic, debilitating inflammatory disorder of the hair follicles that localizes to the intertriginous and anogenital regions of the body. Lesions are characterized by inflammatory nodules, subcutaneous abscesses, fibrosis, and sinus tracts. Crohn's disease (CD) is an idiopathic chronic inflammatory bowel disease that affects any part of the gastrointestinal tract. Multiple treatment options exist for CD, including monoclonal anti-tumor necrosis factor alpha (TNF-α) antibodies like adalimumab (Humira)...
November 2023: Curēus
https://read.qxmd.com/read/38147607/safety-efficacy-and-persistence-of-advanced-therapies-in-inflammatory-bowel-disease-results-from-origins-a-retrospective-observational-study
#18
JOURNAL ARTICLE
Radu Bogdan Mateescu, Cristian Gheorghe, Anca Victorita Trifan, Adrian Saftoiu, Andrada Seicean, Mihai Mircea Diculescu, Christian Banciu, Liliana Simona Gheorghe, Bogdan Busuioc, Adrian Goldis, Daniela Dobru, Ovidiu Fratila, Dumitru Eugen, Simona Bataga, Gabriel Constantinescu, Dan Gheonea, Alina Tantau, Mariana Jinga, Ciprian Brisc, Cristina Cijevschi Prelipcean, Romeo Chira, Carmen Fierbințeanu-Braticevici, Dan Dumitrascu, Monica State, Theodor Voiosu, Lucian Negreanu
BACKGROUND AND AIMS: Real-world assessments of efficacy and safety of advanced therapies used for inflammatory bowel disease (IBD) patients are limited. We aimed to report safety, efficacy and treatment persistence of new molecules (infliximab, adalimumab, vedolizumab, tofacitinib, ustekinumab) in a retrospective multicentric national Romanian analysis. METHODS: We conducted a nationwide, retrospective observational multicentric study. Data were collected retrospectively from electronic and paper files...
December 22, 2023: Journal of Gastrointestinal and Liver Diseases: JGLD
https://read.qxmd.com/read/38114956/effectiveness-and-safety-of-adalimumab-in-patients-with-intestinal-beh%C3%A3-et-s-disease-a-real-world-prospective-observational-study-in-south-korea
#19
MULTICENTER STUDY
Jongwook Yu, Sung Jae Shin, Yune-Jung Park, Hyung Wook Kim, Bo-In Lee, Byong Duk Ye, Geun-Tae Kim, Sung Kook Kim, Joo Sung Kim, Young-Ho Kim, Seonjeong Jeong, Jae Hee Cheon
BACKGROUND: Intestinal Behçet's disease (BD) is characterized by typical gastrointestinal ulcers in patients with BD followed by complications such as bleeding, perforation and fistula. Biologic agents are currently under active investigation to delay the disease course. Various data regarding infliximab are available, but there is relatively lack of data regarding adalimumab. METHODS: This was a multicenter, real-world prospective observational study to evaluate the effectiveness and safety of adalimumab in intestinal BD...
December 19, 2023: BMC Gastroenterology
https://read.qxmd.com/read/38110655/review-of-adalimumab-biosimilar-sb5-in-immune-mediated-inflammatory-diseases
#20
REVIEW
Jonathan Kay, Raymond K Cross, Steven R Feldman, Younjin Park, Stephen B Hanauer
SB5 is an approved biosimilar of adalimumab, a recombinant monoclonal anti-tumor necrosis factor (TNF) antibody. The approval of SB5 was based on the comparison with reference adalimumab in analytical studies, pharmacokinetic (PK) and immunogenicity assessments, and randomized controlled trials. Efficacy data was primarily obtained in patients with rheumatoid arthritis, and extended to include additional indications such as psoriasis, Crohn's disease, or ulcerative colitis by extrapolation. Following its approval, additional post-marketing data have been collected comparing SB5 with reference adalimumab...
December 19, 2023: Advances in Therapy
keyword
keyword
24901
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.